Therapy of perindopril: Organoprotection, not just the antihypertensive effect

Kardiologiya

Volumn 52, Issue 12, 2012, Pages 80-83

  Napalkov, D A ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Arterial hypertension; Organoprotection therapy; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PERINDOPRIL;

EID: 84875658194     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Ranadive S. A., Chen A. X., Serajuddin A. T. Relative lipophilicities and structural-pharmacological considerations of various angiotensinconverting enzyme inhibitors. Pharm Res 1992;9:1480-1486.
2. Holecki M., Szewieczek J., Chudek J. Effects of angiotensin-converting enzyme inhibitors beyond lowering blood pressure - are they important for doctors? Pharm Rep 2011;63:740-751.
3. Fagard R. H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084-1091.
4. Heart Outcomes Prevention Evaluation Study Investigators: Effect of an angiotensin converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
5. Fax KM. (EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators): Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
6. Fenster B. E., Tsao P. S., Rockson S. G. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146:218-226.
7. Bauriedel G., Skowasch D., Schneider M. et al. Antiplatelet effects of angiotensinconverting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry. Am Heart J 2003;145:343-348.
8. Fagari R., Zoppi A. Antihypertensive drugs and fibrinolytic function. Am J Hypertens 2006;19:1293-1299.
9. Miyajima E., Shigemasa T., Yamada Y. et al. Angiotensin II blunts, while an angiotensinconverting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol 1999;26:797-802.
10. Campbell D. J. A review of peridopril in the reduction of cardiovascular events. Vasc Health Risk Man 2006;2:117-124.
11. Kurzen N. P., Fox KM. Do ACE inhibitors modulate atherosclerosis? Eur Heart J 1997;18:1530-1535.
12. European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. 2003. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
13. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003;24:475-484.
14. Ceconi C., Fax KM., Remme W. J. et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73:237-246.
15. Bots M. L., Remme W. J., Lüscher T. F. et al. ACE inhibition and endothelial function: main findings of PERFECT, a substudy of the EUROPA trial. Cardiovasc Drugs Ther 2007;21:269-279.
16. Rodriguez-Granillo GA., Vos J., Bruining N. et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril's prospective Effect on Coronary a Therosclerosis by angiography and Intravascular ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007;100:159-163.
17. Rodriguez-Granillo G. A., de Winter S., Brulning N. et al. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. Eur Heart J 2007;28:2326-2331.
18. Asmar R., London G., O'Rourke M. et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose peridopril/indapamide combination in hypertensive patients. A comparison with atenolol. Hypertension 2001;38:922-926.
19. Asmar R. G., Topouchian J., Pannier B. et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001;19:813-818.
20. Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.
21. Dahlof B., Gosse P., Guerel O. et al. THE P.l. C. X. E. L study: benefits of Preterax on LVH reduction. J Hypertens 2004;22:S410.
22. PREAMI: perindopril and remodelling In elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000;14:671-679.
23. Patel A., MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.
24. Mogensen C. E., Viberti G., Halimi S. et al. Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. Hypertension 2003;41:1063-1071.